Biovitrum Ab Patent-Cliff Exposure & CMS Drug Spending Portfolio

Biovitrum Ab (US): 2 reconciled FDA prescription therapies, $54.9M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$54.9M
2024 Medicare Part D Spend$32.1M
2024 Medicaid Spend$22.8M
California HCAI SB 17 Filings4 WAC filings (max 23.6% 2-yr change)